EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prostaglandin E 2 – EP4 Signaling at the Gut–Immune–Metabolic Interface: A Lipid Mediator Perspective on Obesity and Insulin Resistance

Nila Ganamurali iD, Sarvesh Sabarathinam iD

Comprehensive Physiology · 2026

DOI: 10.1002/cph4.70099 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Comprehensive Physiology, 2026. Verfasst von Nila Ganamurali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaco-Netinformatics Research Lab, Department of Psychiatry, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sc…. Hauptthemen laut MEDLINE: Insulin Resistance, Dinoprostone, Obesity, Receptors, Prostaglandin E, EP4 Subtype. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in dietary and pharmacologic therapies, obesity rates continue to escalate globally. Emerging evidence implicates the gut–immune interface as a key determinant of metabolic dysfunction. This review highlights the prostaglandin E 2 (PGE 2 ) EP4 signaling axis as a pivotal mediator linking gut dysbiosis to systemic insulin resistance. In obesity, elevated COX‐2‐derived PGE 2 reprograms the gut microbiota, depleting short‐chain fatty acid (SCFA)‐producing taxa and reducing regulatory T cell (Treg) homeostasis. The ensuing loss of intestinal integrity promotes metabolic endotoxemia and chronic low‐grade inflammation, culminating in insulin resistance. Targeting the PGE 2 –EP4 microbiota Treg network through EP4 antagonists or microbiome restoration offers a promising therapeutic strategy to restore metabolic balance and prevent obesity associated complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceDinoprostoneObesityReceptors, Prostaglandin E, EP4 SubtypeHumansAnimalsSignal TransductionGastrointestinal Microbiome

Stichwörter der Autor:innen

EP4 receptorgood health and well‐beinggut microbiotainnovationinsulin resistanceprostaglandin E2 (PGE2)short chain fatty acids (SCFAs)

Substanzen

DinoprostoneReceptors, Prostaglandin E, EP4 Subtype

Autor:innen und Institutionen

  • Pharmaco-Netinformatics Research Lab, Department of Psychiatry, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India.

ORCID-Profile: Nila Ganamurali, Sarvesh Sabarathinam

Zitieren

APA

Ganamurali, N., & Sabarathinam, S. (2026). Prostaglandin E 2 – EP4 Signaling at the Gut–Immune–Metabolic Interface: A Lipid Mediator Perspective on Obesity and Insulin Resistance. Comprehensive Physiology. https://doi.org/10.1002/cph4.70099

Vancouver

Ganamurali N, Sabarathinam S. Prostaglandin E 2 – EP4 Signaling at the Gut–Immune–Metabolic Interface: A Lipid Mediator Perspective on Obesity and Insulin Resistance. Comprehensive Physiology. 2026. doi:10.1002/cph4.70099

BibTeX
@article{Ganamurali2026,
  author = {Ganamurali, Nila and Sabarathinam, Sarvesh},
  title = {Prostaglandin E 2 – EP4 Signaling at the Gut–Immune–Metabolic Interface: A Lipid Mediator Perspective on Obesity and Insulin Resistance},
  journal = {Comprehensive Physiology},
  year = {2026},
  doi = {10.1002/cph4.70099}
}
Kostenlos starten →